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ABSTRACT
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate 
cancer which does not respond to hormone therapy. Research of NEPC has been 
hampered by a lack of clinically relevant in vivo models. Recently, we developed 
a first-in-field patient tissue-derived xenograft model of complete neuroendocrine 
transdifferentiation of prostate adenocarcinoma. By comparing gene expression 
profiles of a transplantable adenocarcinoma line (LTL331) and its NEPC subline 
(LTL331R), we identified DEK as a potential biomarker and therapeutic target 
for NEPC. In the present study, elevated DEK protein expression was observed 
in all NEPC xenograft models and clinical NEPC cases, as opposed to their benign 
counterparts (0%), hormonal naïve prostate cancer (2.45%) and castration-resistant 
prostate cancer (29.55%). Elevated DEK expression was found to be an independent 
clinical risk factor, associated with shorter disease-free survival of hormonal naïve 
prostate cancer patients. DEK silencing in PC-3 cells led to a marked reduction in 
cell proliferation, cell migration and invasion. The results suggest that DEK plays an 
important role in the progression of prostate cancer, especially to NEPC, and provides 
a potential biomarker to aid risk stratification of prostate cancer and a novel target 
for therapy of NEPC.
INTRODUCTION
Prostate cancer (PCa) is the most common 
noncutaneous cancer and the second leading cause of death 
from cancer in North American men. Neuroendocrine 
prostate cancer (NEPC) is a highly aggressive subtype 
of PCa, often leading to widespread metastasis and death 
within months of the initial diagnosis. It is characterized 
by small neuroendocrine (NE)-like cells which typically 
express NE markers such as chromogranin A (CHGA) 
and synaptophysin (SYP) and do not express androgen 
receptor (AR) or adenocarcinoma markers, such as 
prostate-specific antigen (PSA) [1, 2]. Pure NEPC is rare 
at initial presentation and is more common in patients 
with a prior history of conventional PCa [3]. In recent 
years, accumulated biological and molecular evidence 
suggests that prostatic adenocarcinoma can undergo a 
NE transdifferentiation following androgen deprivation, 
and eventually progress to NEPC [4, 5]. In view of this, 
the emergence of more potent androgen deprivation 
therapies (e.g., Enzalutamide [6] and Abiraterone 
[7]) will likely increase the incidence of NEPC [8]. 
However, current treatment for NEPC provides only a 
marginal improvement in patients’ survival. Therefore, 
new therapeutic targets and more effective treatments 
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are urgently needed to improve the management of 
the disease.
The research of NEPC has been hampered by a lack 
of clinically relevant experimental in vivo models of the 
disease. Recently, we successfully developed a first-in-field 
model of complete neuroendocrine transdifferentiation 
(LTL331R) of a prostate adenocarcinoma (LTL331). 
The LTL331 retained histological characteristics of 
the original prostate adenocarcinoma of the patient, 
and was strongly positive for PSA and AR. Castration 
of mice carrying LTL331 resulted initially in a drop in 
tumor volume and serum PSA and gave rise to a relapsed 
tumor, LTL331R [9]. The latter was entirely AR and PSA 
negative, uniformly expressed a range of neuroendocrine 
markers, including SYP, CHGA, CHGB and CD56, and 
showed androgen-independent growth. As such, the 
LTL331/LTL331R xenograft model provides a valuable 
tool for studying mechanisms of NEPC progression and 
developing novel therapeutic avenues. Furthermore, 
both LTL331 and LTL331R xenografts exhibited very 
similar copy number profiles, indicating that NEPC 
evolves directly from adenocarcinoma cells rather than 
from clonal selection [4, 5]. The similar genetic profiles 
of LTL331 and LTL331R also suggested that in this case 
genetic alteration may not be the key driver for the NE 
transdifferentiation. Using previously obtained microarray 
gene expression data (GSE 41193) from LTL331 and 
LTL331R prostate cancer xenografts [9], we compiled 
a targeted, literature-driven panel of up-regulated genes 
(compared with adenocarcinomas) which may function 
as epigenetic regulators and critical factors that control 
the development of specific cell lineages. DEK Oncogene 
(DEK), a chromatin modulator, was identified as a 
potential therapeutic target for NEPC.
DEK belongs to a class of DNA topology 
modulators that was originally identified as one part of a 
fusion protein in a subtype of acute myeloid leukemia [10]. 
DEK has been shown to interact with several epigenetic 
modifiers, thereby serving as a hub to recruit histones, 
histone modifiers and chromatin remodeling factors and 
modulate their interaction with DNA [11–13]. Elevated 
expression of DEK has been detected in several types 
of solid tumors [14–18]. It has been suggested that DEK 
may promote tumorigenesis and neoplastic progression 
by its ability to interfere with cell division, inhibit cell 
differentiation, senescence and apoptosis, and to cooperate 
with transforming oncogenes [19–22]. However, the 
biological function of DEK in prostate cancer is not clear.
RESULTS
Elevated DEK expression in multiple NEPC 
xenograft models
To validate the association of DEK expression with 
NEPC, we examined DEK mRNA expression in a panel 
of patient tissue-derived prostate cancer xenograft models. 
We observed significantly increased DEK RNA expression 
in multiple NEPC models (LTL331R, LTL352 and 
LTL370) compared to adenocarcinoma models (Fig. 1A). 
Among hormonal naïve prostate adenocarcinoma 
models, LTL331 showed higher expression of DEK 
compared to the other models (e.g., LTL311, LTL313B 
and LTL418) that did not give rise to NEPC after host 
castration (Fig. 1A). The protein expression of DEK was 
further examined by immunohistochemistry (IHC) in a 
panel of xenograft models. Consistent with their mRNA 
expression, all NEPC models showed strong nuclear 
staining of DEK; elevated nuclear DEK staining was also 
observed in LTL331 compared to other adenocarcinoma 
models (Fig. 1B).
Elevated DEK expression in clinical CRPC and 
NEPC samples
To determine the clinical relevance of DEK in 
NEPC, we mined a clinical cohort that includes 30 
adenocarcinoma and 7 NEPC cases [8]. RNA-seq data 
of this cohort showed that DEK mRNA expression was 
significantly higher in NEPC tissues when compared to 
adenocarcinoma (p < 0.001, Fig. 2A). The expression of 
DEK protein was examined using IHC in independent 
clinical prostate cancer tissue microarrays (TMAs) 
containing 69 benign prostate, 163 adenocarcinoma, 
44 CRPC and 6 NEPC cases. All the benign prostate cases 
and 158 out of 163 (96.93%) hormonal naïve primary 
adenocarcinoma cases showed negative expression of 
DEK protein. 4 out of 163 (2.45%) of primary hormonal 
naïve adenocarcinoma showed weak DEK expression 
and only one case showed strong DEK expression. In 
comparison, an increase in percentage of DEK-positive 
cases was observed in 13 out of 44 (29.55%) CRPC cases 
( p < 0.05). Importantly, strong to moderate nuclear DEK 
expression was observed in all NEPC tissues (6 out of 
6, 100%), that were PSA negative and CHGA positive 
(Fig. 2B, C). The data suggest that increased expression 
of DEK is significantly associated with NEPC progression.
Elevated DEK expression correlates with poor 
prognosis in prostate cancer patients
Increased DEK expression in a small proportion of 
hormonal naïve PCa cases and adenocarcinoma xenograft 
models suggests that increased DEK expression may be 
a pre-disposing factor in hormonal naïve cancers during 
NEPC progression and associated with aggressiveness. 
Therefore, we investigated whether increased DEK 
expression may provide a novel prognostic marker to aid 
risk stratification of hormonal naïve prostate cancers. We 
examined the association of DEK expression with other 
clinicopathological factors including age, serum PSA level, 
Gleason score, pathological stage and lymph node invasion 
Oncotarget1808www.impactjournals.com/oncotarget
Figure 1: DEK expression in patient-tissue derived xenograft models. (A) increased DEK mRNA expression is observed in 
NEPC xenograft models; pre-disposed increased DEK expression is observed in LTL331 compared to other adenocarcinoma xenografts, 
which do not give rise to NEPC after host castration; (B) DEK protein expression is increased in NECP xenograft models compared to 
adenocarcinoma models; stronger DEK staining is observed in LTL331 compared to other adenocarcinoma.
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Figure 2: DEK expression in clinical prostate cancer samples. (A) Elevated DEK mRNA expression is observed in clinical NEPC 
samples compared to adenocarcinoma; (B) Increased DEK protein expression is observed in clinical NEPC samples compared to CRPC, 
hormonal naive adenocarcinoma and benign prostate; (C) Representative images of AR, Chromogranin A and DEK staining in benign 
prostate, adenocarcinoma and NEPC. Inserts show negative DEK expression in chromogranin A positive normal NE cells; (D) Kaplan–
Meier analysis shows that the DEK positive cases had markedly lower relapse-free survival compared with DEK negative cases (p < 0.001).
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status and observed a significant association of DEK 
expression with Gleason grade ( p = 0.003, Table 1). For 
patient survival analysis, a DEK score was used to separate 
patients into two groups: DEK negative group (score < 1) 
versus DEK positive group (score > = 1). Kaplan–Meier 
analysis showed that the DEK-positive group had markedly 
shorter relapse-free survival than the DEK-negative group 
( p < 0.001, hazard ratio = 11.26, 95% confidence interval 
[CI]: 2.702 to 46.92, Fig. 2D). Univariate Cox regression 
analysis showed that Gleason grade, pathological stage, 
lymph node metastasis and DEK expression were 
independent predictors of disease free survival. Cox 
regression analysis of multivariates indicated that elevated 
DEK expression has a relative risk of 6.91 for relapse-free 
patients’ survival (95% CI: 1.33–35.96) with a p = 0.022 
(Table 2). It’s suggested that increased expression of DEK 
is an independent prognostic factor in prostate cancer.
Consistently increased DEK expression during a 
castration time-series of LTL331
We have generated gene expression profile 
data from LTL331 xenografts before and after host 
castration at various time points (unpublished data). 
As expected, expression of many genes involved in 
cellular proliferation, cell cycle and mitosis (e.g., MKI67, 
AURKA and E2F1) was significantly decreased after 
host castration; increased expression was only detected 
in fully relapsed NEPC tissue. In contrast, increased 
DEK expression was observed after castration and 
stayed consistently high during the transformation to 
NEPC (Fig. 3A, B). Moreover, such post-castration 
increase in DEK expression was not observed in other 
adenocarcinoma models that gave rise to AR positive 
relapsed cancers (e.g., LTL418 and LTL313B, Fig. 3B). It 
is suggested that increased expression of DEK is not due 
to highly proliferative characteristics of NEPC, and may 
play an important role in the development of NEPC.
Down-regulation of DEK suppresses prostate 
cancer cell growth, migration and invasion
To study functional roles of DEK in prostate cancer, 
we examined effects of decreased DEK expression on 
PC-3 cells, a cell line characteristic of prostatic small cell 
neuroendocrine carcinoma [23]. A substantial loss of DEK 
expression in cells treated with DEK-targeting siRNA 
compared with those treated with vehicle or non-targeting 
siRNA was confirmed by Western blotting (Fig. 4A). 
Within 96 h after transfection, the total cell number of DEK 
Table 1: Association of DEK expression with clinicopathological factors
Variables Overall DEK- DEK+ p value
Age
0.2
 Mean 62.08 61.95 65.93
 Median 62.69 62.68 67.8
 Range 42.55–78.79 42.55–78.79 58.22–72.12
PSA ng/ml
0.908
 Mean 10.84 10.86 10.13
 Median 7.43 7.47 6.45
 Range 0.53–162.00 0.53–162.00 0.60–27.00
Gleason score
0.003 ≤ 7 109 109 0
 ≥ 8 51 46 5
Pathological stage
0.202 pT1,2 82 81 1
 pT3,4 78 74 4
lymph node invasion status
0.373
 negative 85 83 2
 positive 27 25 2
 not done 48 47 1
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siRNA transfected cells was significantly lower than that 
of control siRNA transfected and mock cells ( p = 0.022; 
Fig. 4B). Cell cycle analysis showed a significant 
G1/S arrest in the DEK siRNA group compared to the 
control and mock groups after release from thymidine 
synchronization ( p < 0.001; Fig. 4C). A similar G1/S 
arrest was also observed in DEK siRNA transfected 
PC-3 cells after treatment of paclitaxel (data not shown). 
In vitro scratch wound-healing and cell invasion assays 
were used to examine the effects of reduced DEK protein 
expression on migration and tissue invasion of PC-3 cells. 
In the wound-healing assays, DEK silencing significantly 
reduced PC-3 cell motility as revealed by a 48-hour wound 
healing assay (DEK vs Mock p = 0.017, DEK vs NC 
p = 0.025; Fig. 4D). In addition, Boyden chamber assays 
showed that DEK knockdown markedly reduced tissue 
invasion of the cells (DEK vs Mock p = 0.049, DEK vs 
NC p = 0.022; Fig. 4E).
Potential DEK-regulated genes involved in cell 
proliferation and metastasis
To gain more detailed insights into the function 
of the DEK gene in NEPC development, we performed 
microarray gene expression analysis on control-treated 
and DEK silenced PC-3 prostate cancer cells. A total of 
825 genes were found to be differentially expressed and 
regulated by DEK under these conditions (Student’s t-test; 
FC > 1.5 and P < 0.05). Biological relevance of the DEK-
regulated genes was further investigated by performing 
IPA gene function enrichment analysis. Top enrichments 
included gene functions related to neuronal development, 
proliferation of prostate cancer cells, cell cycle, cancer 
metastasis, and cell migration (Table 3). Listed genes 
belonging to these functions are likely contributors to the 
DEK-regulated cell proliferation and migration functions 
observed in our in vitro functional analyses.
DISCUSSION
NEPC is a lethal form of AR negative prostate 
cancer with most patients dying within 2 years of 
diagnosis despite very aggressive chemotherapeutic 
regimens [24–26]. This aggressive variant of prostate 
cancer has been increasingly recognized in the clinic. 
However, molecular alterations in NEPC remain largely 
unknown. Recently we successfully developed a first-in-
field complete NE transdifferentiation xenograft model. 
Comparative analysis of gene profiling data of parental 
Table 2: Univariable and multivariable Cox regression analyses predicting disease free survival of 
hormonal naïve prostate cancer patients
Predictors
Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value
Pathologic Gleason
 ≤ 7  1.00 (Ref.) -  1.00 (Ref.) -
 ≥ 8 10.04 (4.3346–23.2829) < 0.001 7.957 (2.7563–22.9727) < 0.001
Pathologic stage
 pT1,2  1.00 (Ref.) -  1.00 (Ref.) -
 pT3,4 4.855 (2.1833–10.7921) < 0.001 1.2047 (0.4323–3.3574) 0.722
PSA ng/ml
 < 10  1.00 (Ref.) -  1.00 (Ref.) -
 ≥ 10 1.723 (0.8389–3.5373) 0.138 0.9989 (0.4626–2.1570) 0.998
lymph node invasion 
status
 negative  1.00 (Ref.) -  1.00 (Ref.) -
 positive 4.9313 (2.3412–10.39) < 0.001 2.539167 (1.15581–5.5782) 0.020
 not done 0.3718 (0.1223–1.13) 0.081 0.794226 (0.21870–2.8843) 0.726
DEK expression
 negatie  1.00 (Ref.) -  1.00 (Ref.) -
 positive 16.9758 (3.587–80.34) < 0.001 6.90537 (1.32614–35.9572) 0.022
HR = hazard ratio; CI = confidence interval
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adenocarcinoma (LTL331) and relapsed NEPC (LTL331R) 
showed increased expression of a panel of NE markers in 
the NEPC model, which is consistent with the findings in 
clinical NEPCs. It is suggested that this model provides 
a valuable tool for identifying key molecules involved in 
NEPC development.
Figure 3: Consistent increased DEK expression during a castration time-series of LTL331. (A) Gene expression array 
analysis showed decreased expression of genes involved in cellular proliferation, cell cycle, and mitosis (i.e. MKI67, AURKA, E2F1), 
while increased expression was only observed in fully transformed NEPC (331R). Consistently increased RNA expression of DEK after 
host castration; (B) During the castration time-series, increased expression of DEK protein was only observed in LTL331, but not in other 
models, such as LTL418, which gives rise to AR positive relapsed tumor, the common form of CRPC in clinic, after host castration.
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Figure 4: Knockdown of DEK suppresses PC-3 cell growth, migration and invasion. (A) siRNA targeting DEK efficiently 
knocks down DEK expression in PC-3 cells; (B) Decreased DEK expression suppresses PC-3 cells growth; (C) Cell cycle analysis shows 
cell cycle was synchronized in each group by thymidine (0 h). 4 h and 8 h after release of thymidine, a significant G1/S arrest was observed 
in the DEK siRNA group compared to control and mock group (X axis: BrdU; Y axis: 7AAD); (D). Wound healing assay showed significant 
suppression of cell migration in DEK knockdown cells; (E) Boyden chamber assay showed significant suppression of tissue invasion in 
DEK knockdown cells.
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Table 3: IPA function analysis of differentially expressed genes after DEK knockdown
Diseases or 
Functions
Predicted 
Activation State
Activation 
z-score*
p-Value Molecules
Analysis based on downregulated genes after DEK knockdown
Cellular Development, Cellular Growth and Proliferation
proliferation of 
prostate cancer 
cell lines
Decreased –2.914 0.007 AKR1C3,ALCAM,CAV1,CDK6,CXCL8
,FGF1,IGFBP5,LZTS1,PRKCI
cell viability Decreased –2.387 0.010
ALPK2,BAG3,BCL2A1,CAMK2D,CAV
1,CCNA2,CDK6,COL4A3,CXCL8,FAN
CA,FGF1,FPGS,ID4,IGFBP5,IL21R,M
DM2,MED21,MMP1,MTMR1,NPY1R,
NUPL1,PGF,POMP,PPM1A,PPP1R11,P
TCH1,PTPRZ1,RRM2,SLC2A1,SUFU
proliferation 
of tumor cell 
lines
Decreased –2.525 0.018
AKR1C3,ALCAM,ARID3A,CAV1,CCN
A2,CDCA4,CDK6,CHN2,COL4A3,CRK,
CXCL8,FANCA,FGF1,GRIA1,HAS2, 
HIAT1,IFNAR1,IGFBP5,KISS1R,LZTS1, 
MDM2,MMP1,PFKFB3,PFKP,PRKCI,PT
CH1,PTPRZ1,RRM2,SLC2A1,SUFU,TA
GLN3,WNT7A
cell survival Decreased –2.59 0.018
ALCAM,ALPK2,BAG3,BCL2A1,
CAMK2D,CAV1,CCNA2,CDK6,C
OL4A3,CXCL8,FANCA,FGF1,FP
GS,ID4,IGFBP5,IL21R,MDM2,M
ED21,MMP1,MTMR1,NPY1R,NU
PL1,PGF,POMP,PPM1A,PPP1R11,-
PTCH1,PTPRZ1,RRM2,SLC2A1,SUFU
Cellular Movement
migration of 
cells Decreased –3.283 0.020
ALCAM,BAG3,BCAT1,CAMK2D,CAV
1,CCNA2,CDK6,CES1,CHN2,COL4A3
,CRK,CXCL8,DEK,DSG2,FCGR2A,FG
F1,FZD4,HAS2,HOXD10,IFNAR1,IGF
BP5,IL21R,KISS1R,LRRC15,MCF2L,M
MP1,MYH10,PAQR3,PGF,PHACTR1,P
OU2AF1,PPM1A,PPM1F,PRKCI,PTP4
A1,PTPRZ1,SDC1,SLC2A1,UTS2
migration of 
tumor cell 
lines
Decreased –2.953 0.001
ALCAM,CAV1,CHN2,COL4A3,CRK,C
XCL8,FGF1,HAS2,IFNAR1,KISS1R,M
CF2L,MMP1,MYH10,PGF,PHACTR1,P
PM1F,PRKCI,PTPRZ1,SDC1,SLC2A1
Cellular Assembly and Organization, Cellular Maintenance, Tissue Development
Formation of 
cytoskeleton Decreased –2.606 0.001
CAPZB,CAV1,CDK6,CRK,CXCL8,FC
GR2A,FGF1,GPR4,KISS1R,MCF2L,PP
M1F,PRKCI,PSRC1
Formation of 
actin filaments
Decreased –2.744 0.002
CAV1,CDK6,CRK,CXCL8,FCGR2A,F
GF1,GPR4,KISS1R,MCF2L,PPM1F,P
RKCI
(Continued)
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In this study, we showed for the first time that DEK, 
a chromatin binding protein, is abnormally expressed 
in NEPC clinical samples and xenograft models and 
is associated with neuroendocrine differentiation. 
Interestingly, the increase of DEK expression was only 
observed in LTL331 but not in other adenocarcinoma 
models that do not give rise to NEPC after host castration. 
Consistently, we observed increased DEK expression 
in only 2.45% of hormonal naive PCa cases and an 
association of increased DEK expression with poor 
clinical outcome. These data indicate that the increase of 
DEK expression may predispose for NEPC development. 
Retrospective examination of DEK expression in 
hormone-naïve tissue specimens from patients who have 
or have not developed NEPC will further validate this 
hypothesis.
There is an urgent need to identify markers to aid 
risk stratification of hormone-naïve prostate cancer. In this 
study, we demonstrated that increased DEK expression 
is an independent prognostic factor in prostate cancer. 
It should be noted that unlike other NE markers, DEK 
expression was not observed in non-proliferative, normal 
NE cells, which indicates that DEK expression is not 
just a reflection of the NE phenotype. It is suggested that 
increased expression of DEK may be associated with the 
aggressiveness of PCa and provides improved prognostic 
information alone or in combination with other NE 
markers. Evaluation using independent patient cohorts will 
be helpful to determine the veracity of the findings.
It remains unclear why DEK expression increased 
during the development of NEPC. It has been reported 
that DEK can be transcriptionally activated by the 
E7 oncogene, a classical negative regulator of the 
retinoblastoma (Rb) protein in human papillomavirus 
(HPV)-positive cervical cancer cells and primary human 
keratinocytes [27, 28]. Moreover, E2F1 was shown 
to be able to bind to the DEK promoter and involve an 
activation of DEK transcription [29]. By examination 
of RNA expression of LTL331 before and a series of 
time points after host castration, we observed decreased 
Diseases or 
Functions
Predicted 
Activation State
Activation 
z-score*
p-Value Molecules
Formation of 
filaments
Decreased –2.606 0.001
CAPZB,CAV1,CDK6,CRK,CXCL8,FC
GR2A,FGF1,GPR4,KISS1R,MCF2L,PK
P1,PPM1F,PRKCI,PSRC1
Growth of 
connective 
tissue
Decreased –2.003 0.004
ARID3A,CAV1,CCNA2,CDK6,CXCL8
,DSG2,FGF1,IFNAR1,IGFBP5,LZTS1,
MCF2L,MDM2,MYH10,NPR3,PAQR3,
PGF,PTCH1,PTPRZ1,UTS2
Cell transformation
Cell 
transformation Decreased –2.675 0.004
ASPH,BCL2A1,CAV1,CCNA2,CDK6,C
RK,FGF1,GPR4,HAS2,MCF2L,MDM2,
PRDX3,PRKCI,PTCH1,WNT7A
Analysis based on upregualated genes after DEK knockdown
Cell Cycle
S phase of 
tumor cell 
lines
Decreased –2.401 0.021 CCNG2,CDH1,ESR2,IL1B,IL6,MXD4,
PMEPA1
Nervous System Development and Function
Morphology of 
nervous system Decreased –2.207 0.003
ASIC3,BMPR1B,CELSR3,COL13A1,C
OLQ,CTSF,DKK1,EGR2,ESR2,GFI1,G
JC2,GLDN,HESX1,HHAT,HOXD3,ID1
,IL1B,IL6,IL6ST,IRX6,KCND2,KCNQ
1,LAMC1,LRRK2,MAGI2,MAPK8IP2,
NAB1,NFATC4,NRP1,NTF4,POU4F1,P
ROS1,RELN,SALL4,SH2D3C,SLC12A
5,SNCA,THRA,UBE4B,UCN
*Positive and negative Z-score cutoffs are ≥ 2.0 and ≤ –2.0, respectively.
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expression of E2F1 in series of post-castration samples, 
whereas increased expression was only detected at the 
last time point, i.e. fully transformed NEPC. Conversely, 
consistently increased DEK RNA and protein expression 
was observed at all the castration time points, suggesting 
that another mechanism beyond E2F1 is involved in the 
regulation of DEK expression. Since increased DEK 
expression was observed immediately after host castration, 
it is possible that DEK is negatively regulated by AR 
signaling in adenocarcinoma. However, this hypothesis 
was not supported by the lack of DEK post-castration 
up-regulation in other adenocarcinoma xenograft models 
(such as LTL313B and LTL418). Investigating the 
mechanisms of regulation in DEK expression will be an 
avenue for future research directions.
The functional role of DEK in prostate cancer is not 
clear. In this study, we observed a significant suppression 
of cell proliferation and cell invasive ability by DEK 
silencing. Cell cycle analysis demonstrated that the 
suppression of cell proliferation was due to a G1/S arrest. 
These findings are consistent with an oncogenic role of 
DEK previously reported in other types of cancer [30, 31]. 
Further comparative gene expression profiling analysis of 
DEK-knockdown and control PC-3 cells demonstrated 
that a number of genes involved in the cell cycle and 
cancer metastasis were differentially expressed after DEK 
knockdown. These potential DEK-regulated genes are 
likely contributors to the DEK-dependent cell proliferation 
and migration functions observed in in vitro functional 
analyses. We also observed a significant decrease in the 
expression of some WNT ligands (WNT7A and WNT7B) 
in DEK silenced PC-3 cells, which is consistent with 
the findings of a recent study in breast cancer that DEK 
can drive the proliferation of cells through stimulated 
expression and secretion of Wnt ligands [31]. It suggested 
that the interaction of DEK and WNT pathways may play 
an important role in multiple types of cancer. Interestingly, 
a number of genes involved in neural system development 
were enriched in the IPA function analysis in our study 
(Table 3). Further study on DEK regulated genes/pathways 
will provide insights to the mechanism of DEK regulated 
NE differentiation of prostate cancer. Recently, DEK was 
identified as an SPOP substrate that exhibited decreases in 
ubiquitylation and proteasomal degradation and increase 
in expression in SPOP-mutant prostate cancer [32]. This 
study showed that in LHMAR and LNCaP cell lines, 
SPOP mutant-related or vector-based overexpression of 
DEK significantly promotes cell invasion and knockdown 
of DEK decreases cell invasion of cells overexpressing 
mutant SPOP, which implicates DEK as an oncogenic 
effector in prostate cancer. This study provides further 
independent evidence for the functional role of DEK in 
prostate cancer.
Currently, there is no effective targeted therapy for 
NEPC patients. New targeted agents in the preclinical and 
clinical development stage, such as an AURKA inhibitor, 
PHA-739358, showed promising effects [8]. AURKA 
is known to play a role in mitosis. Interestingly, in the 
process of NE transdifferentiation of LTL331/LTL331R, 
we observed that a number of genes associated with cell 
proliferation and mitosis (e.g., MKI67, AURKA and E2F1) 
was significantly decreased at multiple time points after 
host castration and increased only in fully relapsed NEPC 
tissue. This suggests that increased expression of these 
genes in NEPC is likely a reflection of highly proliferative 
characteristics of NEPC rather than key regulators of 
NEPC development. On the contrary, we observed 
(1) consistently increased DEK expression in post-
castration LTL331, multiple NEPC models and clinical 
NEPC samples and (2) significant suppression of cell 
proliferation and migration in DEK-depleted cancer cells.
In conclusion, the findings of the present study 
suggest that DEK plays an important role in the 
progression of prostate cancer, especially to NEPC. 
Elevated DEK protein expression may serve as a novel 
prognostic factor for prostate cancer patients. The DEK 
gene may represent a new target for therapy of NEPC.
MATERIALS AND METHODS
Materials and animals
Chemicals, solvents, and solutions were obtained 
from Sigma-Aldrich Canada Ltd, Oakville, ON, Canada, 
unless otherwise indicated. Six- to eight-week old NOD/
SCID IL2 receptor gamma chain null (NSG) mice were 
bred by the BC Cancer Research Centre Animal Resource 
Centre, BC Cancer Agency, Vancouver, Canada.
Xenografts
The patient-derived prostate cancer adenocarcinoma 
tissue lines were maintained via serial transplantation of 
subrenal capsule xenografts in male NSG mice supplemented 
with testosterone, as previously described [33]. NEPC 
xenografts LTL352, LTL370 were maintained in intact male 
NSG. To determine the response of LTL331 to castration, 
the testosterone pellet was removed and mice were castrated 
after tumor volume reached > 200 mm3. Animal care 
and experiments were carried out in accordance with the 
guidelines of the Canadian Council on Animal Care.
Clinical prostate cancer tissues
The prostate cancer specimens (69 benign prostate, 
163 adenocarcinoma, 44 CRPC and 6 NEPC cases) were 
obtained from the Vancouver Prostate Centre Tissue 
Bank. Specimens were obtained from patients, with 
their informed consent, following a protocol approved 
by the Clinical Research Ethics Board of the University 
of British Columbia (UBC) and the BC Cancer Agency. 
Tissue microarrays (TMAs) were constructed [34] at the 
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Prostate Centre, Vancouver General Hospital (VGH). 
The H&E slides were reviewed and the desired areas were 
marked on them and their correspondent paraffin blocks. 
TMAs were manually constructed (Beecher Instruments, 
MD, USA) by punching duplicate cores of 1 mm for each 
sample.
Post-operative follow-up
Following surgery, patients were tested every 
6 months for serum PSA levels. PSA recurrence was 
defined as a sustained elevation, on two or more occasions, 
of serum total PSA > 0.2 ng/ml and was assigned to the 
date of the first elevated value.
Immunohistochemistry
Immunohistochemical staining with monoclonal 
mouse antibody against DEK (BD Biosciences, San Jose, 
CA, USA) was conducted using a Ventana autostainer 
(model Discover XT; Ventana Medical System, Tucson, 
AZ) with an enzyme-labelled biotin-streptavidin 
system and a solvent-resistant DAB Map kit (Ventana). 
All sections used for immunohistochemistry were 
counterstained with 5% (w/v) Harris hematoxylin.
DEK protein staining scoring
DEK nuclear staining of tissues was evaluated 
by two pathologists and given a score of 0, 1, 2 or 3, 
representing no DEK staining, weak, moderate and strong 
DEK staining intensity, respectively.
Cell cultures
Human PC-3 prostate cancer cell lines were obtained 
from the American Type Culture Collection (ATCC, 
Manassas, VA). Cultures were maintained in RPMI-1640 
medium supplemented with 10% fetal bovine serum.
siRNA transfection
Small interfering RNA (siRNA) targeting DEK 
(siDEK) and negative control (scrambled) siRNAs were 
purchased from Dharmacon (Cat. No. L-003881-00 and 
D001810-10, Chicago, IL). Cells were transfected with 
20 nM siRNA in oligofectamine reagent (Invitrogen, 
Carlsbad, CA) following the manufacturer’s instructions.
Western blotting
PC-3 cell lysates were prepared using cell 
lysis buffer supplemented with a protease inhibitor 
cocktail (Roche, Basel, Switzerland); total lysate 
protein was determined using the BCA protein 
assay (Pierce, Rockford, IL). For Western blotting, 
typically 10 μg whole cell lysate was run on 8% SDS 
polyacrylamide gel. The samples were electrotransferred 
to PVDF membrane and nonspecific binding was 
blocked in TBST buffer containing 5% bovine serum 
albumin. The chemoluminescent signal was detected 
using SuperSignal West Femto Maximum Sensitivity 
Substrate (Pierce). The following antibodies were used: 
anti-DEK (BD Biosciences), anti-vinculin (Sigma-
Aldrich).
Wound healing cell migration assay
PC-3 cells were seeded into 6-well culture plates 
using their regular maintenance medium. After the cells 
had reached confluence, the medium was removed and 
a plastic pipette tip was drawn across the center sections 
of the wells to produce clean ~1-mm-wide wounds in the 
monolayers. 0.5 μM mitomycin C was added to the culture 
medium after wounds had been made. Images were taken 
immediately after generating the wound, and after 12, 24 
and 48 hours of incubation. The cell-recovered areas were 
measured to estimate the extent of cell migration [35]. The 
average percent wound healing was determined based on 
3 measurements of the wound area and were expressed as 
means ± SD. Statistical significance was established using 
the Student’s t-test.
Modified boyden chamber assays
Tumor cell invasion assays were performed using 
modified Boyden chambers consisting of 8 μm pore filter 
inserts in 24-well plates (BD Biosciences, San Jose, 
CA) as described elsewhere [35]. PC-3 cells were 
trypsinized and resuspended in serum-free RPMI-1640 
medium and plated on Matrigel-coated membranes of 
the upper compartments. Cells were incubated at 37°C 
for 22 hours in a CO
2
 incubator, using 5% fetal bovine 
serum in the lower chambers as a chemoattractant. 
Following incubation, the inserts were pulled out and the 
non-invading cells on the upper surface were removed 
with a cotton swab. The cells on the lower surface of the 
membrane were fixed in 4% paraformaldehyde, air-dried 
and stained with DAPI VECTASHIELD solution (Vector 
Laboratories Inc., Burlingame, CA). Membranes were 
scanned using a Zeiss AxioPlan 2 fluorescent microscope. 
The number of invaded cells was counted. Results were 
expressed as means ± SD. Statistical significance was 
established using the Student’s t-test.
Total RNA isolation and quantitative Real-Time 
PCR (qRT-PCR)
Total RNA was isolated from cultured cells using 
the RNeasy mini kit (Qiagen Inc., Hilden, Germany) 
following the manufacturer’s instructions. Total 
RNA (1 μg) was used to synthesize cDNAs using a 
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QuantiTect Reverse Transcription Kit (Qiagen Inc.). 
qRT-PCR reactions using KAPA SYBR Fast Universal 
(Kapa Biosystems, Woburn, MA) were performed in a 
ViiA 7 Real-Time PCR system (Applied Biosystems, 
Foster City, CA). The primer sequences used are DEK, 
forward 5′ -GCCGAAATCCGCGGTTCA-3′ and reverse 
5′-CTCTCTCTGTAAGGAAGAGACTTGC-3′; GAPDH, 
forward 5′-CACCAGGGCTGCTTTTAACTC-3′ and 
reverse 5′-GACAAGCTTCCCGTTCTCAG-3′.
Microarray analysis
RNA for microarray analysis was extracted from 
two replicates of siDEK knockdown and siControl treated 
PC-3 cells. RNA sample quality was assessed with the 
Agilent 2100 Bioanalyzer and NanoDrop ND-2000 UV-
VIS spectrophotometer, such that only samples with 
RNA Integrity Number (RIN) ≥ 8.0, A260/280 OD values 
between 1.8 and 2.0, and an A260/A230 OD value of 2.0 
were used for one-color labelling using Agilent’s One-
Colour Microarray-Based Gene Expression Analysis Low 
Input Quick Amp Labelling v6.0 (Agilent Technologies, 
Santa Clara, CA). 100 ng of total RNA was used to 
generate cyanine-3-labelled cRNA. RNA from samples 
were hybridized on Agilent SurePrint G3 Human GE 
8x60K Microarray v2 (Design ID 039494). Arrays were 
scanned with an Agilent DNA Microarray Scanner at a 
3 μm scan resolution and image data were processed with 
Agilent Feature Extraction 11.0.1.1. Processed signals 
were quantile normalized with Agilent GeneSpring 12.0. 
Raw expression data have been deposited in the NCBI’s 
Gene Expression Omnibus and are accessible through 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token= 
erqxugakzjmrrwp&acc=GSE61214.
Biostatistical or bioinformatics analysis
Microarray gene expression data were filtered 
to improve data quality prior to downstream analysis. 
Only probes with gene annotations and detectable 
expression levels (greater than 3 in log2 scale) were 
retained. Differentially expressed genes induced by 
DEK knockdown were identified as genes with > 1.5 
fold difference in the siDEK-treated samples relative to 
the control samples and with p-value < 0.05 (Student’s 
t-test). Significantly differentially expressed genes were 
interpreted for functional gene enrichments using the 
Ingenuity Pathway Analysis software (IPA; June 2014 
release). Statistical over-representation of functions was 
calculated using the Fischer’s exact test and Benjamini-
Hochberg (BH) multiple-test correction method.
Statistical analysis
The t-test was used to compare mean DEK protein 
expressions between each pathological group. The Kaplan–
Meier method was used to estimate curves for relapse-free 
survival and comparisons were made with the use of the 
log-rank test. Hazard ratios were calculated using Cox 
proportional hazard models. The Student’s t test was used 
for comparison of in vitro studies. All tests of significance 
were two sided, and differences were considered 
statistically significant with p values less than 0.05.
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